AbbVie 10-Q, filed Aug 3, 2026

Summary

AbbVie reported worldwide net revenues of $32.0 billion for the six months ended June 30, 2026, up 11% on a reported basis, with operating earnings of $10.4 billion, diluted earnings per share of $2.42 and cash flows from operations of $7.3 billion. The company said that under a January 2026 voluntary agreement with the U.S. government it will offer low prices in Medicaid, expand direct-to-patient offerings and pledge $100 billion in U.S.-based research, development and capital investment over the next decade, in exchange for a three-year exemption from tariffs and future price mandates.

Key points

• H1 2026 net revenues rose 11% on a reported basis and 10% at constant currency, with results including $3.4 billion in intangible amortization and $3.9 billion from a change in fair value of contingent consideration liabilities.
• CMS selected Botox as one of 15 medicines subject to government-set Medicare Part B and Part D prices beginning in 2028 under the Inflation Reduction Act of 2022.
• AbbVie's pipeline has approximately 90 compounds, devices or indications, about 60 in mid- and late-stage development.
• AbbVie received a Complete Response Letter from the FDA for trenibotulinumtoxinE (Boey) for glabellar lines requesting more information on manufacturing processes, while the European Commission approved the product for that use; the FDA approved Decnupaz for BPDCN and the EC approved Rinvoq for non-segmental vitiligo and severe alopecia areata.

Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.